非洲背景下自采样与临床医生采样HPV检测在不同筛查策略中的准确性:系统综述与Meta分析
该系统综述与Meta分析检索截至2022年2月7日的多个数据库,纳入28项研究(21项进入Meta分析),评估非洲背景下自采样与临床医生采样检测高危HPV的一致性。合并Cohen kappa为0.66(95%CI:0.61-0.71),自采样检测高危HPV的敏感性接近80%、特异性接近90%。作者认为自采样与临床医生采样一致性为中等至相当,即时检测可能特别适合低收入和中等收入国家的宫颈癌初级筛查。
要点
- 非洲背景下自采样与临床医生采样HPV检测合并Cohen kappa为0.66(95%CI:0.61-0.71),一致性中等至相当。
- 基于PCR的靶标扩增检测kappa为0.68(95%CI:0.63-0.73),优于等温mRNA检测的0.61(95%CI:0.51-0.71)。
- 即时检测kappa为0.73(95%CI:0.67-0.80),自采样检测高危HPV敏感性接近80%、特异性接近90%。
核心结论
- 在非洲背景下,自采样与临床医生采样的一致性为中等至相当。
- 即时检测可能特别适合低收入和中等收入国家的宫颈癌初级筛查。
- 使用自采样时应特别关注高危人群,且应建立筛查方案。
研究设计与样本
- 系统综述与Meta分析,检索Pubmed、Livivo、Web of Science、Cochrane Library和African Index Medicus,检索日期为2022年2月7日。
- 纳入标准为报告自采样与临床医生采样对比、研究地点在非洲、报告Cohen kappa或自采样检测敏感性及特异性。
- 系统综述纳入28项研究,Meta分析纳入21项研究;采用随机效应模型合并Cohen kappa及敏感性、特异性估计。
- 研究注册于PROSPERO(CRD42020218081)。
主要发现
- 自采样用于检测高危HPV感染,两项研究额外检测低危HPV感染。
- 合并Cohen kappa为0.66(95%CI:0.61-0.71);高危人群为0.63(95%CI:0.56-0.71)。
- 基于PCR的靶标扩增检测kappa为0.68(95%CI:0.63-0.73),等温mRNA检测为0.61(95%CI:0.51-0.71)。
- 即时检测kappa为0.73(95%CI:0.67-0.80)。
- 自采样检测高危HPV的敏感性接近80%,特异性接近90%。
临床怎么用
- 作者认为即时检测可能特别适合低收入和中等收入国家的宫颈癌初级筛查。
- 作者指出使用自采样时应特别关注高危人群。
- 作者建议应建立筛查方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Cervical cancer still poses a considerable threat to women in low- and middle-income countries, particularly on the African continent. Self-collection of a vaginal sample promises advantages over the established sampling by clinicians. We aimed to assess the accuracy of self-sampling compared to clinician sampling in order to inform its application in primary care in the African context. METHODS: We searched Pubmed, Livivo, Web of Science, Cochrane Library and African Index Medicus on the 07th of February 2022. The eligibility criteria were: reporting (i) self-sampling against clinician-sampling, (ii) study location in Africa, (iii) relevant outcome-measures: (a) Cohen's kappa (b) sensitivity and specificity of self-sampling tests. We combined Cohen's kappa effects, additionally sensitivity and specificity estimates using random-effects models. The study is registered with PROSPERO (CRD42020218081). RESULTS: We included 28 studies in the systematic review and 21 studies in the meta-analysis. Self-sampling was used to test for high-risk HPV infections. Two studies additionally tested for low-risk HPV infections. The pooled Cohen's kappa was 0.66 (95%CI: 0.61-0.71). Populations at risk yielded 0.63 (95%CI: 0.56-0.71). Target amplification tests based on PCR performed best with a kappa of 0.68 (95%CI: 0.63-0.73) compared to isothermal mRNA tests, 0.61 (95%CI: 0.51-0.71). Point of care tests performed exceptionally well, 0.73 (95%CI: 0.67-0.80). Sensitivities are close to 80% and specificities close to 90% of self-sampling to detect high-risk HPV. CONCLUSIONS: Self-sampling agrees moderately to substantially with clinician sampling in the African context. Point of care tests might be particularly suited for application in cervical cancer primary screening in low- and middle-income countries. Populations at risk should get special attention while using self-sampling. Screening protocols should be established.
引用
- Sy F, Greuel M, Winkler V, et al. Accuracy of HPV testing on self-collected and clinician-collected samples for different screening strategies in African settings: A systematic review and meta-analysis. Gynecol Oncol. 2022. PMID: 35781165. doi:10.1016/j.ygyno.2022.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。